We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Compugen Expands and Strengthens Business Development Team
News

Compugen Expands and Strengthens Business Development Team

Compugen Expands and Strengthens Business Development Team
News

Compugen Expands and Strengthens Business Development Team

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Compugen Expands and Strengthens Business Development Team"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Compugen Ltd. has announced the appointment of Dr. Felix Karim as Vice President Corporate & Business Development, effective March 2, 2015. Dr. Karim, who will be based at Compugen’s South San Francisco facilities, will report to Dr. Anat Cohen-Dayag, Compugen’s President and Chief Executive Officer, and will have direct responsibility for the Company’s business development strategy and its execution.

Dr. Cohen-Dayag, President and CEO of Compugen, stated, “We are very pleased to welcome Felix to Compugen’s senior management team. Felix brings to Compugen substantial experience and accomplishments in a range of biopharma companies, from start-ups to leading public companies, initially as a senior scientist and project leader, and later as an executive with broad responsibilities in both R&D and business development. We are excited to have the benefit of his experience and capabilities as we evaluate a number of potential collaboration options to maximize the value of our attractive early stage target pipeline and our unique, broadly applicable predictive discovery capabilities.”

Dr. Karim has significant experience in the biopharmaceutical industry and has held various executive roles in business development and R&D management. His most recent position prior to joining Compugen was Head of External R&D (licensing) for the San Francisco region at Amgen.

Before Amgen, Dr. Karim was Vice President of Business Development at KAI Pharmaceuticals, where he led business development and transaction activities, including the sale of KAI Pharmaceuticals to Amgen.

Dr. Karim has also held various positions at Exelixis and Celera Genomics, leading multidisciplinary teams across a broad range of activities in R&D and program development, and has played an integral role in business development efforts that resulted in significant pharma partnerships.

Dr. Karim holds a bachelor’s degree in biochemistry from the University of California, Berkeley, and a PhD from the Department of Human Genetics at the University of Utah Medical School.

Advertisement